What factors influence the decision to initiate anti-VEGF injections to prevent radiation retinopathy after plaque brachytherapy?

A great and timely question!

There is increasing evidence, based on several retrospective series, that prophylactic use of anti-VEGF agents (particularly bevacizumab) may provide better visual and structural (avoiding neovascular complications) in post-plaque melanoma patients. This is with injections given at 4-month intervals for at least the first two years in eyes with tumors that are at high risk for radiation retinopathy. These would be tumors posterior to the equator, larger tumors, macul...